Ventyx Biosciences Inc (VTYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.51 Million) by net assets ($191.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VTYX stock market capitalisation for the company's overall valuation and market capitalisation.
Ventyx Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Ventyx Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ventyx Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ventyx Biosciences Inc ranked by their cash flow conversion efficiency. See debt repayment capacity of Ventyx Biosciences Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
N/A |
|
Shaanxi Fenghuo Electronics Co Ltd
SHE:000561
|
-0.062x |
|
Bio-Thera Solutions Ltd
SHG:688177
|
-0.324x |
|
Glenveagh Properties PLC
IR:GVR
|
0.096x |
|
Kingsgate Consolidated Ltd
AU:KCN
|
0.153x |
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
0.143x |
|
Jiangsu Yinhe Electronics Co Ltd
SHE:002519
|
-0.009x |
|
CSSC Offshore & Marine Engineering (Group) Co Ltd
F:GSZ
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Ventyx Biosciences Inc from 2019 to 2024. View today's stock price for Ventyx Biosciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $254.04 Million | $-130.87 Million | -0.515x | +24.54% |
| 2023-12-31 | $243.92 Million | $-166.52 Million | -0.683x | -144.60% |
| 2022-12-31 | $353.89 Million | $-98.77 Million | -0.279x | -101.61% |
| 2021-12-31 | $279.20 Million | $-38.65 Million | -0.138x | -168.50% |
| 2020-12-31 | $-30.65 Million | $-6.20 Million | 0.202x | -68.42% |
| 2019-12-31 | $-4.13 Million | $-2.64 Million | 0.640x | -- |
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more